Histone Deacetylase Inhibitors Augment Antitumor Efficacy of Herpes-based Oncolytic Viruses (Q44640557)

4 December 2017

title

Histone Deacetylase Inhibitors Augment Antitumor Efficacy of Herpes-based Oncolytic Viruses (English)

1 reference

4 December 2017

1 reference

Akihiro Otsuki

1

1 reference

4 December 2017

Ankita Patel

2

1 reference

4 December 2017

Kazue Kasai

3

1 reference

4 December 2017

Masataka Suzuki

4

1 reference

4 December 2017

Kazuhiko Kurozumi

5

1 reference

4 December 2017

E Antonio Chiocca

6

1 reference

4 December 2017

Yoshinaga Saeki

7

1 reference

4 December 2017

publication date

1 September 2008

1 reference

4 December 2017

1 reference

4 December 2017

volume

16

1 reference

4 December 2017

issue

9

1 reference

4 December 2017

page(s)

1546-1555

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

4 December 2017

1 reference

7 January 2021

Recent progress in the battle between oncolytic viruses and tumours

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

Oncolytic herpes simplex virus vectors for cancer virotherapy

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

Identification of human brain tumour initiating cells

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

Viruses and interferon: a fight for supremacy

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

Macrophages and cytokines in the early defence against herpes simplex virus

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

Early STAT1 activation after systemic delivery of HSV amplicon vectors suppresses transcription of the vector-encoded transgene

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

An immunocompetent murine model for oncolysis with an armed and targeted measles virus.

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

Histone deacetylases and cancer

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

Histone deacetylase inhibitors in cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

Histone deacetylases and cancer: causes and therapies

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

Amplification of recombinant adenoviral transgene products occurs by inhibition of histone deacetylase

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

Amplification of transgene expression in vitro and in vivo using a novel inhibitor of histone deacetylase.

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity.

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1.

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

Histone deacetylase inhibitors suppress IFNalpha-induced up-regulation of promyelocytic leukemia protein

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

Imaging immediate-early and strict-late promoter activity during oncolytic herpes simplex virus type 1 infection and replication in tumors

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

Engineering oncolytic measles virus to circumvent the intracellular innate immune response

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

Matrix metalloproteinases-1 and -8 improve the distribution and efficacy of an oncolytic virus

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

Herpes simplex virus 1 gamma(1)34.5 gene function, which blocks the host response to infection, maps in the homologous domain of the genes expressed during growth arrest and DNA damage

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

HSV-1 ICP34.5 confers neurovirulence by targeting the Beclin 1 autophagy protein

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275.

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520.

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

MRI of transgene expression: correlation to therapeutic gene expression

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.155

7 January 2021

Identifiers

DOI

10.1038/MT.2008.155

1 reference

4 December 2017

1 reference